Leonardo Punzi

Prof. Leonardo Punzi

Center for Gout and Bone & Joint Metabolic Diseases, SS Giovanni e Paolo Hospital, Venice, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2019 in Foods
Verified
Journal Article
Open access
PDF file
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero
YCYessica Zamudio Cuevas
Yessica Zamudio Cuevas
Elisa BelluzziElisa Belluzzi
Elisa Belluzzi
LALisa Andretto
Lisa Andretto
ASAnna Scanu
Anna Scanu
Leonardo PunziLeonardo Punzi
Leonardo Punzi
Resveratol (RES) and its natural precursor polydatin (PD) are polyphenols that may display a broad variety of beneficial effects including anti-inflammatory properties. This study aimed to investigate the role of RES and PD in the inflammatory process induced by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals in vitro. A monocytic cell line (THP-1) was primed for 3 hours with phorbol myristate acetate (100 ng/mL) and stimulated with synthetic MSU (0.05 mg/mL) and CPP (0.025 mg/mL) crystals. RES and PD were added to cultures concurrently with the crystals, or as 2-hour pretreatment. The effect of the two polyphenols was evaluated on intracellular and extracellular IL-1β levels, NACHT-LRRPYD-containing protein-3 (NLRP3) inflammasome expression, reactive oxygen species (ROS) and nitric oxide (NO) production, and the assessment of crystal phagocytosis. RES and PD strongly inhibited IL-1β induced by crystals after cell pretreatment. Cell pretreatment was effective also in reducing IL-1 mRNA expression while no effect was observed on NLRP3 gene expression. RES and PD had no effect on crystal phagocytosis when used as pretreatment. Both polyphenols were significantly effective in inhibiting ROS and NO production. Our results demonstrated that RES and PD are effective in inhibiting crystal-induced inflammation. Data obtained after cell pretreatment allow us to hypothesize that these polyphenols act on specific signaling pathways, preventing inflammation.

19 November 2020 in Reumatismo
Verified
Journal Article
Open access
PDF file
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero
RRRoberta Ramonda
Roberta Ramonda
Ariela HoxhaAriela Hoxha
Ariela Hoxha
ASAnna Scanu
Anna Scanu
Paola GalozziPaola Galozzi
Paola Galozzi
Leonardo PunziLeonardo Punzi
Leonardo Punzi
The aim of this study was to evaluate the effect of an oral preparation containing a naturally occurring matrix of hydrolyzed collagen type II, chondroitin sulfate (CS), and hyaluronic acid (HA), and bioactive oligopeptides of natural hydrolyzed keratin (K) in patients affected by knee OA through the evaluation of synovial fluid (SF) and clinical changes before and after treatment. Thirty patients with knee OA and swollen joint were included in the study and submitted to arthrocentesis. Patients were randomized in two groups: 1) the treatment group (N.15) took a dietary supplement containing 120 mg HA, 240 mg CS and 300 mg K once a day for 4 weeks; 2) the control group (N.15) was only submitted to arthrocentesis. Patient symptoms were evaluated at the beginning and at the end of the study by the WOMAC self-assessment questionnaire, the Lequesne algofunctional index, and the VAS forms. SF changes were evaluated by measuring local inflammatory indices, cytokines IL-1β, IL-8, IL-6, IL-10 and GM-CSF. The group of patients treated with the oral supplement showed an improvement in the clinical indices WOMAC (p<0.01), Lequesne (p=0.014) and VAS pain (p<0.01). On the contrary, no significant changes were found in the control group. The SF collected from the treated group showed a reduction of IL-8 (p=0.015), IL-6 and IL-10 levels, while no changes in cytokines were observed in the control group. This pilot study suggests that an oral administration of a preparation containing a combination of HA, CS and K can improve some clinical parameters and affect cytokine concentrations in SF in patients with knee OA.

1 September 2020
Verified
Journal Article
Closed access
Leonardo PunziLeonardo Punzi
Leonardo Punzi
ASA. Scanu
A. Scanu
PGP. Galozzi
P. Galozzi
RLR. Luisetto
R. Luisetto
PSP. Spinella
P. Spinella
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero

24 January 2024 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
Leonardo PunziLeonardo Punzi
Leonardo Punzi
PGPaola Galozzi
Paola Galozzi
RLRoberto Luisetto
Roberto Luisetto
ASAnna Scanu
Anna Scanu
RRRoberta Ramonda
Roberta Ramonda
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero
Review; Authors: L. Punzi, P. Galozzi, R. Luisetto, A. Scanu, R. Ramonda, F. Oliviero

13 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero
Paola GalozziPaola Galozzi
Paola Galozzi
ASAnna Scanu
Anna Scanu
FGFrancesca Galuppini
Francesca Galuppini
VLVanni Lazzarin
Vanni Lazzarin
RLRoberto Luisetto
Roberto Luisetto
Background: Polydatin is a stilbenoid with important antioxidant, anti-inflammatory, and immunomodulating properties. The aim of this study was to assess the anti-inflammatory preventive effect of polydatin in the mouse model of acute arthritis induced by calcium pyrophosphate (CPP) crystals. Methods: Acute arthritis was induced by the injection of a suspension of sterile CPP crystals into the ankle joint of Balb/c mice. Animals were randomized to receive polydatin or colchicine (the control drug) according to a prophylactic and a therapeutic protocol. The primary outcome was the variation of ankle swelling obtained after crystal injection and treatment, while histological parameters such as leukocyte infiltration, IL-1ß and CXCL1 levels and tissue expression were considered as secondary outcomes. Results: Prophylactic treatment with PD significantly diminished ankle swelling after 48 h from crystal injection. Secondary outcomes such as leukocyte infiltration, necrosis, edema, and synovitis were also decreased. PD caused a reduction in circulating levels of IL-1ß and CXCL1, as well as their tissue expression. By contrast, the therapeutic administration of PD did not have any beneficial effect. Conclusions: PD can effectively prevent acute inflammatory response to crystals in the mouse model of CPP crystal-induced arthritis. These results suggest that this bioactive compound might be used in the prevention of crystal-induced acute attacks in humans.

Verified
Journal Article
Open access
PDF file
ASAnna Scanu
Anna Scanu
RLRoberto Luisetto
Roberto Luisetto
Francesca OlivieroFrancesca Oliviero
Francesca Oliviero
FGFrancesca Galuppini
Francesca Galuppini
VLVanni Lazzarin
Vanni Lazzarin
Leonardo PunziLeonardo Punzi
Leonardo Punzi
We investigated the effects of bactericidal/permeability-increasing protein (BPI) alone or in combination with hyaluronic acid (HA) in two animal models: collagen-induced arthritis (CIA) and crystal-induced inflammation. In CIA, mice were intraperitoneally injected with PBS, HA, or BPI plus or minus HA, twice a week for 2 months, and then euthanized to collect paw and blood. Arthritis was assessed in ankle joints by clinical and histological evaluation. Pathogenic crystals were intraperitoneally injected in mice plus or minus BPI, or with a composition of BPI and HA. After sacrifice, total and differential leukocyte counts were determined. Cytokine levels were measured in serum and peritoneal fluids. In CIA mice, BPI improved clinical and histological outcomes (histological scores ≥2-fold), and downregulated inflammatory mediators (47–93%). In crystal-induced inflammation, BPI reduced leukocyte infiltration (total count: ≥60%; polymorphonuclear cells: ≥36%) and inhibited cytokine production (35–74%). In both models, when mice were co-treated with BPI and HA, the improvement of all parameters was greater than that observed after administration of the two substances alone. Results show that BPI attenuates CIA and inflammation in mice, and this effect is enhanced by HA co-administration. Combined use of BPI and HA represents an interesting perspective for new potential treatments in arthritis.